Investors Face November Deadline in Beta Bionics Class Action Lawsuit

The complaint, Holtzman v. Beta Bionics, Inc. et al., alleges that the firm misled shareholders regarding the reliability of its iLet Bionic Pancreas insulin pump. Plaintiffs claim the device utilized an aggressive automated dosing algorithm prone to malfunctions, which allegedly led to hundreds of life-threatening hypoglycemic events requiring emergency medical intervention. According to the filing, Beta Bionics failed to investigate or report thousands of customer complaints to the FDA, concealing the true extent of the device's technical instability.

Furthermore, the lawsuit contends that a June 2025 FDA Form 483 inspection revealed over 18,000 unreported complaints, contradicting company assertions that the agency’s concerns were merely minor interpretive differences. The firm allegedly failed to implement corrective actions, resulting in a formal FDA warning letter regarding its quality management and reporting systems. Investors seeking to serve as lead plaintiff in the recovery effort must act by the November 3 deadline, though participation in potential settlements does not strictly require lead plaintiff status.